Published in Int J Radiat Oncol Biol Phys on January 15, 1997
Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol (2008) 2.30
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer (2005) 1.68
Prostate cancer: 7. Radiation therapy for localized disease. CMAJ (1998) 1.38
Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer (2002) 0.98
Antiandrogens in prostate cancer. Invest New Drugs (1999) 0.86
Neoadjuvant Therapy for Prostate Cancer: An Oncologist's Perspective. Rev Urol (2003) 0.84
Complications and functional results of surgery for locally advanced prostate cancer. Adv Urol (2012) 0.83
Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art. Cancer Manag Res (2010) 0.81
Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure. Int J Clin Oncol (2006) 0.81
Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. Int J Radiat Oncol Biol Phys (1997) 0.80
Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer. J Biomed Biotechnol (2009) 0.80
External beam radiation therapy: role of androgen deprivation. World J Urol (2003) 0.79
Short-term versus long-term hormone therapy plus radiotherapy or prostatectomy for prostate cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol (2013) 0.79
Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer. Br J Cancer (2002) 0.78
Management of locally advanced prostate cancer: new definitions and strategies. West J Med (1998) 0.78
Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients. World J Surg Oncol (2015) 0.77
Multimodal approaches to high-risk prostate cancer. Curr Oncol (2010) 0.76
Neoadjuvant hormonal therapy in men being treated with radiotherapy for localized prostate cancer. Rev Urol (2004) 0.75
Radiation treatment for patients with intermediate-risk prostate cancer. Ther Adv Urol (2012) 0.75
Therapeutic strategies for localized and locally advanced prostate cancer: combining androgen suppression with definitive local therapy. Rev Urol (2003) 0.75
Selecting treatment for high-risk, localized prostate cancer: the case for radiation therapy. Rev Urol (2002) 0.75
Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy? Radiat Oncol J (2014) 0.75
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA (1995) 4.45
Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate (1999) 4.12
Isolation of an RNA with the properties of haemoglobin messenger. Nature (1969) 3.53
A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res (2010) 3.15
Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta. Mol Endocrinol (1997) 2.58
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A (1982) 2.38
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate (1983) 2.29
SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab (2006) 2.25
Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell (1999) 2.17
The impact of family history on early detection of prostate cancer. Nat Med (1995) 2.14
[Fetal macrosomia: management, obstetrical and neonatal results. Multicenter case-control study in 15 maternity hospitals in Paris and the Ile de France area]. Gynecol Obstet Fertil (2002) 2.09
The fragile X mental retardation protein is associated with poly(A)+ mRNA in actively translating polyribosomes. Hum Mol Genet (1997) 2.08
Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. Mol Endocrinol (1991) 2.07
Tuberculosis morbidity amongst immigrants: notification and hospitalization. Community Med (1979) 2.00
Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res (2010) 1.99
Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab (1997) 1.96
Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol (1992) 1.84
Assignment of the human 3 beta-hydroxysteroid dehydrogenase gene (HSDB3) to the p13 band of chromosome 1. Cytogenet Cell Genet (1989) 1.70
Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab (1994) 1.66
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med (1982) 1.65
Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem (1988) 1.60
Brief overview of maternal triglycerides as a risk factor for pre-eclampsia. BJOG (2006) 1.59
Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem (2000) 1.59
Correlation between maximum cervical dilatation at cesarean delivery and subsequent vaginal birth after cesarean delivery. Obstet Gynecol (1997) 1.58
Localization of oestrogen receptor alpha, oestrogen receptor beta and androgen receptors in the rat reproductive organs. J Endocrinol (2000) 1.57
Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology (1996) 1.56
p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Eur J Cancer B Oral Oncol (1996) 1.54
Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity. Urology (1997) 1.53
Intact "biological motion" and "structure from motion" perception in a patient with impaired motion mechanisms: a case study. Vis Neurosci (1990) 1.53
Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril (1994) 1.50
A heterogeneous set of FMR1 proteins is widely distributed in mouse tissues and is modulated in cell culture. Hum Mol Genet (1995) 1.50
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med (1992) 1.50
Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate. Lancet (1984) 1.49
Increased cortisol levels and impaired cognition in human aging: implication for depression and dementia in later life. Rev Neurosci (1999) 1.47
Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 GY in 7 weeks. Int J Radiat Oncol Biol Phys (1996) 1.46
Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer (2003) 1.44
The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care (1996) 1.43
Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet (1996) 1.42
Prostate cancer. Lancet (1994) 1.40
The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia (2011) 1.39
Genetic control of susceptibility to infection with Mycobacterium tuberculosis in mice. Genes Immun (2000) 1.38
Important prognostic value of standardized objective criteria of response in stage D2 prostatic carcinoma. Eur J Cancer Clin Oncol (1988) 1.38
Immunohistochemical localization of beta-lipotropic hormone in the pituitary gland. Endocrinology (1977) 1.38
DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids (1998) 1.35
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet (1998) 1.35
Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution. Structure (1995) 1.30
Placenta percreta: balloon occlusion and embolization of the internal iliac arteries to reduce intraoperative blood losses. Am J Obstet Gynecol (1997) 1.29
Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol (2005) 1.27
Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release. J Biol Chem (1978) 1.26
Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol (1985) 1.26
Molecular cloning of human type 3 3 alpha-hydroxysteroid dehydrogenase that differs from 20 alpha-hydroxysteroid dehydrogenase by seven amino acids. Biochem Biophys Res Commun (1996) 1.25
Genetic control of blood parasitaemia in mouse malaria maps to chromosome 8. Nat Genet (1997) 1.22
Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Arch Sex Behav (1988) 1.21
Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: unique importance of extratesticular androgens in men. J Steroid Biochem (1989) 1.18
Development of the hypothalamic-pituitary-thyroid axis in the neonatal rat. Endocrinology (1975) 1.16
Unique features of the basal cells of human prostate epithelium. Microsc Res Tech (2000) 1.16
Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells. J Biol Chem (1990) 1.15
Reproducibility, bioinformatic analysis and power of the SAGE method to evaluate changes in transcriptome. Nucleic Acids Res (2005) 1.14
Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology (1999) 1.14
In vitro interactions of gastrointestinal hormones on cyclic adenosine 3':5'-monophosphate levels and amylase output in the rat pancreas. Gastroenterology (1975) 1.12
Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. Biochem Biophys Res Commun (1976) 1.12
Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J Steroid Biochem Mol Biol (1992) 1.11
Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate (1995) 1.11
Immunization survey of non-institutionalized adults--Quebec (as of May 30, 1996). Can Commun Dis Rep (1996) 1.10
Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab (1997) 1.10
Ocular toxicity of Anandron in patients treated for prostatic cancer. Br J Ophthalmol (1986) 1.10
The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology (1985) 1.10
The nuclear jet and counterjet region of the radio galaxy Cygnus A. Proc Natl Acad Sci U S A (1995) 1.08
Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol (1996) 1.08